Genor Biopharma Holdings Limited
HKEX:6998.HK
1.65 (HKD) • At close September 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 6.488 | 6.488 | 1.478 | 1.478 | 0 | 0 | 0 | 0 | 3.287 | 3.287 | 3.757 | 0 | 1.315 |
| Cost of Revenue
| 0 | 0 | 31.378 | 0 | 0.098 | 0.098 | 0.394 | 0.394 | 0 | 0 | 0 | 0 | 0.88 | 0.88 | 0.837 | 0 | 0.919 |
| Gross Profit
| 0 | 0 | -31.378 | 0 | 6.39 | 6.39 | 1.085 | 1.085 | 0 | 0 | 0 | 0 | 2.408 | 2.408 | 2.92 | 0 | 0.396 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0.985 | 0.985 | 0.734 | 0.734 | 0 | 0 | 0 | 0 | 0.732 | 0.732 | 0.777 | 0 | 0.301 |
| Reseach & Development Expenses
| 169.751 | 169.751 | 112.388 | 112.388 | 144.371 | 144.371 | 147.57 | 147.57 | 170.596 | 170.596 | 135.764 | 135.764 | 174.388 | 174.388 | 236.355 | 111.443 | 70.353 |
| General & Administrative Expenses
| 26.297 | 26.297 | 36.322 | 36.322 | 25.034 | 25.034 | 42.032 | 42.032 | 44.965 | 44.965 | 58.71 | 58.71 | 73.892 | 73.892 | 79.745 | 13.912 | 1.194 |
| Selling & Marketing Expenses
| 0 | 0 | 41.657 | 0 | 10.047 | 10.047 | 31.525 | 31.525 | 35.744 | 35.744 | 13.558 | 13.558 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 26.297 | 26.297 | 36.322 | 36.322 | 35.081 | 35.081 | 73.556 | 73.556 | 80.709 | 80.709 | 72.268 | 72.268 | 73.892 | 73.892 | 79.745 | 13.912 | 1.194 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -16.823 | 16.823 | 2.993 |
| Operating Expenses
| 205.247 | 205.247 | 147.892 | 147.892 | 167.48 | 167.48 | 218.834 | 218.834 | 246.733 | 246.733 | 197.104 | 197.104 | 1,255.233 | 1,255.233 | 299.277 | 142.178 | 74.54 |
| Operating Income
| -164.673 | -164.673 | -143.473 | -143.473 | -174.859 | -174.859 | -217.75 | -217.75 | -244.994 | -244.994 | -197.104 | -197.104 | -214.982 | -214.982 | -386.048 | -142.787 | -74.144 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -26.951 | -26.951 | -147.327 | -147.327 | 0 | 0 | 0 | 0 | -65.404 | -65.404 | -102.754 | 0 | -56.383 |
| Total Other Income Expenses Net
| -35.995 | -35.995 | 5.393 | 5.393 | 13.275 | 13.275 | 13.124 | 13.124 | 15.088 | 15.088 | -6.144 | -6.144 | -1,034.536 | -1,034.536 | -7.671 | -0.769 | -0.173 |
| Income Before Tax
| -200.668 | -200.668 | -138.08 | -138.08 | -161.584 | -161.584 | -204.626 | -204.626 | -229.906 | -229.906 | -203.247 | -203.247 | -1,249.518 | -1,249.518 | -393.719 | -143.556 | -74.317 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -24.905 | -24.905 | -138.448 | -138.448 | 0 | 0 | 0 | 0 | -380.139 | -380.139 | -104.796 | 0 | -56.515 |
| Income Tax Expense
| 0.582 | 0.582 | 0.559 | 0.559 | 0.305 | 0.305 | 1.317 | 1.317 | 1.509 | 1.509 | 1.975 | 1.975 | 1.559 | 1.559 | -1.649 | -1.039 | 0.57 |
| Net Income
| -199.905 | -199.905 | -137.276 | -137.276 | -162.292 | -162.292 | -202.816 | -202.816 | -232.166 | -232.166 | -200.447 | -200.447 | -1,246.859 | -1,246.859 | -392.07 | -142.517 | -74.887 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -25.014 | -25.014 | -137.223 | -137.223 | 0 | 0 | 0 | 0 | -379.33 | -379.33 | -104.357 | 0 | -56.948 |
| EPS
| -0.39 | -0.39 | -0.27 | -0.27 | -0.32 | -0.32 | -0.41 | -0.41 | -0.47 | -0.47 | -0.41 | -0.41 | -4.93 | -4.93 | -0.81 | -0.3 | -0.16 |
| EPS Diluted
| -0.39 | -0.39 | -0.27 | -0.27 | -0.32 | -0.32 | -0.41 | -0.41 | -0.47 | -0.47 | -0.41 | -0.41 | -4.93 | -4.93 | -0.81 | -0.3 | -0.16 |
| EBITDA
| -143.957 | -143.957 | -131.547 | -131.547 | -166.787 | -166.787 | -207.491 | -207.491 | -234.432 | -234.432 | -185.663 | -185.663 | -208.165 | -208.165 | -386 | -130.91 | -64.195 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -25.707 | -25.707 | -140.386 | -140.386 | 0 | 0 | 0 | 0 | -63.33 | -63.33 | -102.742 | 0 | -48.817 |